Ridgetech Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the unaudited interim financial results for Ridgetech Inc. for the six months ended September 30, 2025. The Company, a Cayman Islands exempted company, operates as a wholesale distributor of pharmaceutical and healthcare products in China. Following a strategic restructuring completed on February 28, 2025, the Company divested its retail pharmacy operations (Jiuxin Investment) and acquired Ridgeline and its subsidiary Allright, shifting its focus to online and offline wholesale distribution. The divested retail operations are reported as discontinued operations.
Key Financial Metrics
| Metric | Six Months Ended Sep 30, 2025 | Six Months Ended Sep 30, 2024 |
|---|---|---|
| Net Revenue | $62,805,015 | $62,841,121 |
| Gross Profit | $2,464,195 | $2,414,547 |
| Gross Margin | 3.9% | 3.8% |
| Operating Loss | $(74,293) | $422,416 (Income) |
| Net Loss (Continuing Ops) | $(60,167) | $486,751 (Income) |
| Net Loss (Total) | $(60,167) | $(2,277,092) |
| Cash from Operations | $5,346,634 | $(9,954,817) |
| Cash & Equivalents (End) | $13,935,407 | $12,779,781 |
| Restricted Cash (End) | $4,109,953 | $5,761,294 |
| Total Debt (Notes Payable) | $4,659,329 | $10,386,612 |
| Shareholders' Equity | $29,779,593 | $29,636,382 |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue remained flat (-0.1%), but the mix shifted significantly. Offline wholesale revenue decreased by 21.6% to $51.7 million due to the discontinuation of credit sales to mitigate risk from delayed customer repayments. Conversely, online platform revenue increased by $11.1 million (100% growth) following the acquisition of Allright.
- Profitability: The Company transitioned from a net income of $486,751 in the prior period to a net loss of $60,167. This was driven by a 87.2% increase in selling expenses (primarily distribution fees for new online customers) and a slight decline in offline gross margins to 3.3%.
- Cash Flow: Operating cash flow improved dramatically from a $9.95 million outflow in 2024 to a $5.35 million inflow in 2025, largely due to changes in working capital (increases in accounts payable and receivables).
- Debt Reduction: Notes payable decreased by approximately $5.7 million, from $10.4 million to $4.7 million, reflecting significant repayments.
Outlook, Risks, and Subsequent Events
Management Commentary: Management believes the Company has sufficient resources to operate for the next 12 months. The online segment (Allright) commands a higher gross margin (7.0%) compared to offline wholesale (3.3%) by serving smaller pharmacies and clinics that cannot source directly from manufacturers. However, the Company notes limited bargaining power in the offline market without exclusive agency status.
Risks: The Company's ability to continue as a going concern depends on aligning funding sources with expenditure requirements and repaying short-term debts. PRC regulations restrict dividend payments from subsidiaries to the parent company.
Subsequent Event: On October 30, 2025, the Company entered into a private placement agreement to sell 4,680,000 ordinary shares at $0.60 per share and warrants for 11,700,000 shares at $1.60 per share, raising gross proceeds of $2,808,000.
Investor Verification Checklist
- Verify the sustainability of the 7.0% gross margin in the newly acquired online segment versus the 3.3% offline margin.
- Confirm the status of the $4.66 million utilized in bank acceptance notes and the availability of the remaining $5.07 million credit line with Hangzhou United Bank.
- Assess the impact of the discontinued credit sales policy on future offline revenue growth.
- Review the terms and dilution impact of the October 30, 2025, private placement of shares and warrants.
- Monitor the Company's ability to maintain positive operating cash flow given the historical volatility in working capital.